HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Christer Betsholtz Selected Research

Antibodies

12/2022ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma.
10/2009Antibodies blocking adhesion and matrix binding domains of laminin-332 inhibit tumor growth and metastasis in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Christer Betsholtz Research Topics

Disease

15Neoplasms (Cancer)
12/2022 - 01/2002
6Inflammation (Inflammations)
01/2022 - 01/2016
5Proteinuria
06/2022 - 08/2003
5Hypoxia (Hypoxemia)
01/2020 - 10/2003
5Fibrosis (Cirrhosis)
01/2018 - 01/2009
4Neoplasm Metastasis (Metastasis)
11/2020 - 03/2006
4Atherosclerosis
08/2016 - 10/2002
3IGA Glomerulonephritis (IGA Nephropathy)
06/2022 - 10/2017
3Neuroinflammatory Diseases
01/2022 - 01/2011
3Albuminuria
01/2021 - 01/2011
3Neurodegenerative Diseases (Neurodegenerative Disease)
01/2020 - 01/2015
2Glioma (Gliomas)
12/2022 - 01/2019
2Infections
06/2022 - 02/2021
2Hemorrhage
06/2022 - 11/2021
2Pathologic Processes
01/2022 - 01/2013
2Traumatic Brain Injuries (Traumatic Brain Injury)
01/2022 - 05/2012
2Stroke (Strokes)
01/2021 - 01/2011
2Melanoma (Melanoma, Malignant)
11/2020 - 01/2009
2Brain Neoplasms (Brain Tumor)
01/2020 - 01/2011
2Coronary Artery Disease (Coronary Atherosclerosis)
01/2017 - 08/2016
2Emphysema
04/2016 - 01/2015
2Brain Diseases (Brain Disorder)
07/2014 - 01/2011
2Ischemia
01/2013 - 07/2008
2Alzheimer Disease (Alzheimer's Disease)
05/2012 - 02/2007
2Diabetic Retinopathy (Retinopathy, Diabetic)
08/2011 - 08/2002
2Diabetic Angiopathies (Diabetic Angiopathy)
04/2004 - 01/2004
1Disease Progression
06/2022
1Critical Illness (Critically Ill)
06/2022
1COVID-19
06/2022
1Central Nervous System Diseases (CNS Diseases)
01/2022
1Arthritis (Polyarthritis)
01/2022
1Experimental Arthritis
01/2022
1Rheumatoid Arthritis
01/2022
1Epilepsy (Aura)
01/2022
1Glomerulonephritis
01/2022
1Osteoarthritis
01/2022
1Schizophrenia (Dementia Praecox)
01/2022
1Seizures (Absence Seizure)
01/2022
1Myofibromatosis
01/2021
1Glioblastoma (Glioblastoma Multiforme)
01/2021
1Coronary Occlusion
01/2021
1Myocardial Infarction
01/2021
1Circulating Neoplastic Cells
01/2020
1Cerebrovascular Disorders (Cerebrovascular Occlusion)
11/2019

Drug/Important Bio-Agent (IBA)

10Proto-Oncogene Proteins c-sis (Platelet Derived Growth Factor B)IBA
01/2020 - 08/2002
7Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA
11/2021 - 01/2004
7Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
01/2021 - 10/2002
5Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
06/2017 - 10/2002
4Proteins (Proteins, Gene)FDA Link
12/2022 - 11/2012
4platelet-derived growth factor C (PDGF-C)IBA
04/2016 - 07/2008
4Platelet-Derived Growth FactorIBA
01/2009 - 10/2002
3RNA (Ribonucleic Acid)IBA
01/2022 - 08/2016
3Pharmaceutical PreparationsIBA
01/2022 - 01/2009
3LigandsIBA
01/2021 - 01/2018
3Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2020 - 01/2009
3LipidsIBA
01/2019 - 08/2016
3Protein Isoforms (Isoforms)IBA
12/2016 - 01/2007
3Retinaldehyde (Retinal)IBA
01/2007 - 08/2003
2AntibodiesIBA
12/2022 - 10/2009
2CytokinesIBA
06/2022 - 01/2022
2Semaphorins (Semaphorin)IBA
01/2022 - 01/2016
2Antigen-Antibody Complex (Immune Complex)IBA
01/2022 - 10/2017
2Immunoglobulin A (IgA)IBA
01/2022 - 10/2017
2CollagenIBA
01/2022 - 10/2009
2Tissue Plasminogen Activator (Alteplase)FDA Link
01/2021 - 07/2008
2Streptozocin (Streptozotocin)FDA Link
01/2021 - 01/2016
2Glucose (Dextrose)FDA LinkGeneric
01/2019 - 01/2019
2Messenger RNA (mRNA)IBA
01/2018 - 09/2014
2Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2018 - 06/2010
2platelet-derived growth factor AIBA
12/2016 - 01/2016
2LipopolysaccharidesIBA
01/2016 - 01/2009
2IntegrinsIBA
12/2013 - 10/2009
2Apolipoproteins E (ApoE)IBA
09/2005 - 10/2002
1G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
12/2022
1dendrinIBA
06/2022
1Angiopoietin-2IBA
06/2022
1ThrombomodulinIBA
06/2022
1TIE-2 Receptor (Receptor, TIE 2)IBA
06/2022
1RepSoxIBA
01/2022
1Adenosine Triphosphate (ATP)IBA
01/2022
1Complement System Proteins (Complement)IBA
01/2022
1Kainic Acid (Kainate)IBA
01/2022
1Methotrexate (Mexate)FDA LinkGeneric
01/2022
1Neuropilin-2IBA
01/2022
1KATP ChannelsIBA
01/2022
1Claudin-5IBA
01/2022
1Angiotensin-Converting Enzyme 2IBA
02/2021
1Immunoglobulin G (IgG)IBA
01/2021
1Collagen Type I (Type I Collagen)IBA
01/2021
1Vascular Endothelial Growth Factor BIBA
01/2021
1Small Cytoplasmic RNAIBA
01/2021
1IgA receptor (protein B)IBA
11/2020
1Glucocorticoid Receptors (Glucocorticoid Receptor)IBA
01/2020
1calcium phosphateIBA
01/2020
1Cholesterol 24-Hydroxylase (CYP46A1)IBA
12/2019
1Lipoproteins (Lipoprotein)IBA
01/2019

Therapy/Procedure

8Therapeutics
12/2022 - 05/2009
1Immunotherapy
12/2022
1Thrombolytic Therapy
01/2021
1Cranial Irradiation
01/2020